Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VDJ-006
- Development stage
- Unknown
- Lead developer
- Beijing VDJBio
01
Overview
VDJ-006 is a biological drug candidate developed by Beijing Weidejie Biotechnology. It acts as an antagonist of the interleukin-1 receptor type 1 (IL1R1), functioning as an interleukin-1 receptor alpha antagonist. The primary therapeutic area for VDJ-006 is immune system diseases, with a specific focus on atopic dermatitis. Its mechanism involves blocking IL1R1-mediated signaling, which plays a key role in inflammatory and immune responses. As of May 2025, the highest development status for VDJ-006 is IND (Investigational New Drug) application, indicating it has not yet entered clinical trials or received regulatory approval[1][2][4].
- Other names
- VDJ-006VDJ006VDJ 006
02
Targets
IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on VDJ-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VDJ-006.